Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Richardson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Hospital Pediatrics|December 10, 2013
Pediatric head trauma: abuse or not?Nicholas C Richardson, David I Rappaport
Frontiers in Cell and Developmental Biology|December 26, 2022
Neuronal cilia in energy homeostasisKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Primary cilia and BBS4 are required for postnatal pituitary developmentKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Developmental Biology|January 9, 2026
Primary cilia and BBS4 are required for postnatal pituitary developmentKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular LymphomaKristen Britton, Upendra Mahat, Nicholas C Richardson, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA PerspectiveAndrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Hospital Pediatrics|December 10, 2013
Pediatric head trauma: abuse or not?Nicholas C Richardson, David I Rappaport
Frontiers in Cell and Developmental Biology|December 26, 2022
Neuronal cilia in energy homeostasisKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Primary cilia and BBS4 are required for postnatal pituitary developmentKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Developmental Biology|January 9, 2026
Primary cilia and BBS4 are required for postnatal pituitary developmentKathryn M Brewer, Katlyn K Brewer, Nicholas C Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular LymphomaKristen Britton, Upendra Mahat, Nicholas C Richardson, et al.
The Oncologist|March 28, 2019
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell LymphomaNicholas C Richardson, Yvette L Kasamon, Haiyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
The Oncologist|June 16, 2021
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaYvette L Kasamon, Lauren S L Price, Olanrewaju O Okusanya, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 3, 2023
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018Nadia Howlader, Elad Sharon, Manami Bhattacharya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA PerspectiveAndrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, et al.
Pageof 2